QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 enlivens-elvn-001-shows-anti-cml-activity-in-patients-with-atypical-fusion-transcripts-will-present-data-from-the-ongoing-enable-phase-1a1b-clinical-trial-of-elvn-001-on-a-subset-of-chronic-myeloid-leukemiapatients-at-the-ash-2025-annual-meeting

ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcriptsGrowing unme...

 enliven-therapeutics--files-for-mixed-shelf-size-not-disclosed

-SEC Filing

 enliven-therapeutics-q2-eps-049-beats-054-estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-enliven-therapeutics-raises-price-target-to-48

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...

 goldman-sachs-initiates-coverage-on-enliven-therapeutics-with-buy-rating-announces-price-target-of-37

Goldman Sachs analyst Salveen Richter initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announc...

 baird-maintains-outperform-on-enliven-therapeutics-raises-price-target-to-52

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $...

 enliven-therapeutics-prices-underwritten-public-offering-of-839m-shares-at-1966shr

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the di...

 enliven-therapeutics-launches-200m-public-offering-with-option-for-30m-upsize

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the di...

 enliven-therapeutics-announced-updated-data-from-phase-1-enable-clinical-trial-evaluating-elvn-001-in-patients-with-chronic-myeloid-leukemia-in-an-oral-presentation-at-european-hematology-association-2025-congress

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achievingMMR by 24 weeks, which cont...

 jones-trading-maintains-buy-on-enliven-therapeutics-lowers-price-target-to-27

Jones Trading analyst Soumit Roy maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $3...

 hc-wainwright--co-maintains-buy-on-enliven-therapeutics-raises-price-target-to-40

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...

 enliven-therapeutics-q1-eps-057-misses-049-estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate o...

 enliven-therapeutics-announces-updated-data-from-phase-1-enable-clinical-trial-evaluating-elvn-001-in-patients-with-cml-in-abstract-accepted-for-oral-presentation-at-eha-2025-congress

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which cont...

 hc-wainwright--co-maintains-buy-on-enliven-therapeutics-raises-price-target-to-39

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...

 enliven-therapeutics-q4-2024-gaap-eps-046-beats-052-estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of ...

 btig-initiates-coverage-on-enliven-therapeutics-with-buy-rating-announces-price-target-of-42

BTIG analyst Justin Zelin initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION